Atezolizumab Plus Bevacizumab for TACE ‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT

阿替唑单抗 贝伐单抗 医学 肿瘤科 单克隆 临床试验 内科学 梅德林 癌症研究 单克隆抗体
作者
Kazuomi Ueshima,Kaoru Tsuchiya,Tatsuya Yamashita,Shigeo Shimose,Kazushi Numata,Yuzo Kodama,Shinji Itoh,Yasuhito Tanaka,Hidekatsu Kuroda,Kazuyoshi Ohkawa,Teiji Kuzuya,Masafumi Ikeda,Youhei Kooka,Hiroshi Aikata,Atsushi Hiraoka,Michihisa Moriguchi,Ryosuke Tateishi,Sadahisa Ogasawara,Kouji Yamamoto,Masatoshi Kudo
出处
期刊:Liver International [Wiley]
卷期号:45 (12): e70379-e70379 被引量:6
标识
DOI:10.1111/liv.70379
摘要

BACKGROUND AND AIMS: The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)-naïve patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-7 criteria, meeting its primary endpoint of progression-free survival (PFS). Here, we report the final overall survival (OS) analysis. METHODS: Enrolled patients were naïve to TACE with unresectable intermediate-stage HCC beyond up-to-7 criteria, had Child-Pugh A, Eastern Cooperative Oncology Group performance status 0/1 and received no previous systemic therapy. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered every 3 weeks. The primary endpoint was the 6-month PFS rate by modified Response Evaluation Criteria in Solid Tumours for HCC (mRECIST); secondary endpoints included OS, PFS by RECIST version 1.1, objective response rate (ORR) and safety. RESULTS: Overall, 74 patients were enrolled between December 2020 and September 2021. At the clinical cut-off date (March 31, 2024), median follow-up was 33.6 months. Median PFS by mRECIST was 9.1 months (95% CI 7.1-10.2). Median OS was 33.8 months (95% CI 22.6-not estimable). ORR was 40.5% (95% CI 29.3-52.6), with 12.2% of patients having a complete response. Overall, 82.4% of patients received subsequent therapy. All-cause adverse events (AEs) were observed in 98.6% of patients, most commonly hypertension (71.6%) and proteinuria (54.1%). Grade 3/4 AEs occurred in 43.2% of patients; no Grade 5 AEs were reported. CONCLUSIONS: These results show that atezolizumab plus bevacizumab can be an alternative treatment option for patients with intermediate-stage HCC beyond up-to-7 criteria who are deemed unsuitable for TACE. TRIAL REGISTRATION: jRCTs071200051.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
奇崽完成签到,获得积分10
刚刚
搜集达人的应助被yy采纳,获得10
1秒前
1秒前
1秒前
1秒前
旻洛完成签到 ,获得积分10
1秒前
零的孤心俱乐部完成签到,获得积分10
2秒前
魔修完成签到,获得积分10
2秒前
人生海海完成签到,获得积分20
2秒前
3秒前
小青完成签到 ,获得积分10
3秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
隐形曼青的应助被粒粒采纳,获得10
4秒前
4秒前
4秒前
刻苦冬菱完成签到,获得积分10
5秒前
ZJY完成签到,获得积分10
5秒前
勤恳浩然发布了新的文献求助10
5秒前
再睡亿分钟完成签到,获得积分10
5秒前
衣锦夜行发布了新的文献求助10
6秒前
SCI的豆发布了新的文献求助10
6秒前
6秒前
7秒前
小安的应助被yu采纳,获得10
8秒前
1122发布了新的文献求助10
8秒前
8秒前
上官若男的应助被一只小绵羊采纳,获得50
8秒前
zhangyupei发布了新的文献求助10
8秒前
香蕉觅云的应助被受伤白安采纳,获得10
8秒前
9秒前
9秒前
jane完成签到 ,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651